about
Comparative interspecies investigation on osteoblast cultures: data on cell viability and synthetic activity.Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastasesTumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines updateAre risk factors common to thyroid cancer and nodule? A forty years observational time-trend studyDoes large needle aspiration biopsy add pain to the thyroid nodule evaluation?Atherosclerosis and cancer: common pathways on the vascular endothelium.Changing the endocrine dependence of breast cancer: data and hypotheses.Defining the critical hurdles in cancer immunotherapy.Controversies in diagnostic approaches to the indeterminate follicular thyroid nodule.Thyroid nodule evaluation: what have we really learned from recent clinical guidelines?Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues.Cytokines in breast cancer.Metastatic breast cancer: an updating.Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology.Thyroid fine needle aspiration: how to improve clinicians' confidence and performance with the technique.Defective generation and maturation of dendritic cells from monocytes in colorectal cancer patients during the course of disease.Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.Cytokines in the management of high risk or advanced breast cancer: an update and expectation.Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.Stem cells: their role in breast cancer development and resistance to treatment.Targeted therapies of metastatic breast cancer: relationships with cancer stem cells.Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment.A systemic approach to cancer treatment: tumor cell reprogramming focused on endocrine-related cancers.Interlinking of hypoxia and estrogen in thyroid cancer progression.Neuroendocrine tumors of the lung: hystological classification, diagnosis, traditional and new therapeutic approaches.The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer.Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy.Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer.Immunotherapy and Hormone-therapy in Metastatic Breast Cancer: A Review and an Update.Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).An iron regulatory gene signature in breast cancer: more than a prognostic genetic profile?Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis.Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate.CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis.A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect.Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: a case-control study.Large needle aspiration biopsy histology for preoperative selection of Hürthle cell thyroid nodules.Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer.
P50
Q30777856-299779A9-9DD9-4440-B683-58627078460AQ33264119-0C633A8C-C5D8-4A32-809C-CAE24E2D8446Q34441837-6F143C89-2F04-4633-A1DD-2F4DBDFF2BF3Q34464599-124A1ADF-B1F9-4AAF-A6E2-086B273A9D24Q34639091-F06B409D-9602-4400-A7A1-876435B3E368Q34990177-4E833121-F801-49E1-A76B-7439AE8E574AQ35058816-04CC7349-FE85-4025-BEA9-AF466B98A20FQ35916968-6D0CF7A0-2EFF-426E-84E5-FEA49243EA47Q36275796-9EA7E902-0716-4BC3-9532-CE214AEBD43DQ36564368-D237D16A-16A9-47DC-934C-ECEAD139092CQ36576230-9F6A6BBB-7335-4861-92C6-0D59AF6EF170Q36576294-FE624CA5-0A60-415C-AD09-6E568BE5DA75Q36584748-C34445BD-E47D-4673-9856-F7AA7D7D014FQ36612077-54F223C8-966C-49C5-9721-9E241706E033Q37126953-6FAA02FD-1FB4-455C-B22B-1C4C83A309F5Q37375412-A664FFE2-A783-4627-AA97-F6C9254AB801Q37582064-0134980F-359F-4427-9271-272309164D00Q37660484-6536ABA8-98A8-4532-B59C-0271EE5F20DCQ37786295-89B40299-214A-4996-965E-6DAB8DF9C9BEQ37806268-0B4E129B-0394-4844-AAC3-9A59A408AC8DQ38104130-80DD91EA-5730-4EDB-9C1A-EE11461588D9Q38137559-498A9430-DA6A-43A4-BA0B-8E14A2191076Q38168599-5E437842-C105-4F3E-B02A-C464EDD539B0Q38168600-99058AD9-79D1-472E-9E15-AB1520C57884Q38168602-20AD7ECA-9771-48EE-8F73-6D61FDA21155Q38552196-C5CB4B59-7B6C-4140-99E9-F2C7F89BC885Q38581583-50C94609-306C-46D6-993A-F84D0AD1F39CQ38623670-0DC1C1A4-52D1-48CD-87FC-DDB024817425Q38722568-1BD07843-5BA5-444E-85D3-B0B539494CEAQ39161262-CFA675BC-E304-4F75-9424-CF04172FFF8EQ39652263-E032C738-D7FD-45B6-9ABB-82DD741775B5Q40059411-90E66256-A42D-400E-B26F-AD3E0A8FDE91Q42509575-94A4B5CD-59E1-4A62-9FFA-76AC203B3E86Q42987652-3A2A5572-CDE9-4467-ACB8-38BFCFE14167Q43000487-113D2D40-1EE5-4012-A344-B3A6CF1EA736Q44606339-FC0DE0C5-0623-4516-9FEC-559421A8400AQ44627486-0C466896-EAAF-48FC-92F7-F179BACEC3ADQ45221451-1DC590C2-8393-4C45-848B-AE56D2BAAC21Q45992313-39590562-A8EB-419F-9819-AD3E66A60D4BQ47143199-36BDDA34-5104-4BC0-97E1-5A381BEA10BA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrea Nicolini
@ast
Andrea Nicolini
@en
Andrea Nicolini
@es
Andrea Nicolini
@nl
Andrea Nicolini
@sl
type
label
Andrea Nicolini
@ast
Andrea Nicolini
@en
Andrea Nicolini
@es
Andrea Nicolini
@nl
Andrea Nicolini
@sl
prefLabel
Andrea Nicolini
@ast
Andrea Nicolini
@en
Andrea Nicolini
@es
Andrea Nicolini
@nl
Andrea Nicolini
@sl
P106
P1153
7006511647
P31
P496
0000-0002-5178-9510